Biogen Stock Falls on Alzheimer’s Drug Trial Miss
AI Summary
Biogen's stock has sharply declined following the failure of its Alzheimer's drug trial. This setback raises concerns about the company's future prospects in the biotech sector.
Related Articles
China’s desire for endless youth is wiping out donkeys – can scientists help?
South China Morning Post —
Indo-US defence ties: Jaishankar pushes ‘Make in India’ approach in talks with Rubio
The Times of India —
Hong Kong’s Paul Chan urges closer Europe ties, dialogue to work out differences
South China Morning Post —
Atalanta manager confirms Ederson set for transfer amid Man United links
Yahoo Sports —
'Dhurandhar 2' BO day 67: Can Ranveer Singh film net Rs 1150 crore this weekend?
The Times of India —
ECB rate hike odds rise as Iran conflict fuels inflation
Investing.com —